GSBR-1290 is a small molecule commercialized by Structure Therapeutics, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of GSBR-1290’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GSBR-1290 is expected to reach an annual total of $57 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GSBR-1290 Overview
GSBR-1290 is under development for the treatment of type 2 diabetes and obesity. It is administered through oral route as capsules or tablets. The therapeutic candidate acts as glucagon-like peptide-1 (GLP1) receptor agonist. It is developed based on the Schrodinger artificial intelligence (AI) technology.
Structure Therapeutics Overview
Structure Therapeutics is a health tech company that provides life-changing medicines for patients using advanced computational and structure-based technology. Structure Therapeutics is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$52.6 million in FY2022, compared to an operating loss of US$37.7 million in FY2021. The net loss of the company was US$51.3 million in FY2022, compared to a net loss of US$38.1 million in FY2021.
For a complete picture of GSBR-1290’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.